Device Trial Radar · NCT04812444
Peripheral Venous Stent System in the Treatment of Iliac Vein Stenosis or Occlusion
Last checked: Nov 20, 2026Latest source record: Oct 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
220
Actual
Start
Oct 9, 2020
Primary completion
Oct 20, 2023
Study completion Oct 20, 2023
Sponsor
- Lead sponsor
- Zhejiang Zylox Medical Device Co., Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 23, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Clinical study on safety and efficacy of Zylox peripheral venous stent system in the treatment of iliac vein stenosis or occlusion.
Conditions
- Iliac Vein Stenosis
- Iliac Vein Occlusion
Interventions
Zylox Peripheral Venous StentDevice
Self-expanding stent implantation during the index procedure.
Zilver Vena Venous StentDevice
Self-expanding stent implantation during the index procedure.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Target vascular patency rate at 12 months after operationTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.